Transforming Clinical Development with Remote Patient Monitoring
Leverage clinical and data science to maximize trial success and accelerate decision-making.
Increase Drug Exposure
Anticipate SAEs to sustain optimal dosing and treatment continuity.
Improve patient engagement
Boost trial adherence with personalized digital follow-up and >85% questionnaire completion.
Streamlined ClinOps
Reduce burden for Patients, Healthcare Providers and Sponsors.
Stronger submission package
Strengthen regulatory submissions with real-time, FDA-grade PRO-CTCAE data for robust tolerability evidence.
Advanced Analytics
Identify optimal dosing and refine inclusion criteria through advanced analytics and outlier detection.
Real-World Benchmark
Create synthetic control arms by comparing trial data with Resilience’s real-world oncology database.
Our Technology for Clinical Development
Digital tools designed to make oncology trials faster, safer, and more efficient.
Patient-Centric App
Collection of ePROs and QoL data (PRO-CTCAE, QoL questionnaires) to improve adherence and patient experience.
Remote Patient Monitoring
Real-time symptom alerts review to streamline prioritization and patient management
Advanced Analytics Platform
Real-time data analytics to monitor adherence, support dose optimization decisions & Benchmark with Resilience Real-World Database
Why Pharma & Biotech Trust Resilience Care
Raising trial standards with real-world care expertise and a network of 150+ cancer centers and leading phase I units
Scientific & Medical DNA
Co-founded by the Gustave Roussy Institute, Class IIa Medical Device in Europe & Enforcement Discretion from the FDA in the US
Innovative Trial Design
Project Optimus : Complying with the FDA’s latest guidances, bringing patient-centricy to early-phase trials
Real-World Leadership
First RPM Tool to be reimbursed by payers in Europe, relying on an extensive network of 150+ cancer centers, with 100k+ patients monitored by the end of 2026
Strong Pharma/Biotech Track Record
Supporting 20+ oncology trials including industrial sponsors globally
Built for the Entire Clinical Trial Team
Addressing all key stakeholders involved in the patient journey — from clinicians, to sponsors and patients themselves.
Early detection of efficacy and safety trends via longitudinal symptom data
Real-time access to patient-reported outcomes supporting informed dosing decisions
Better adherence to protocol through continuous patient engagement
Integrated alerts and dashboards to facilitate medical decision-making during the trial
Decrease burden on PIs: less patient phone calls, emergency visits and unplanned hospitalizations
Primary users: 95% of alerts are managed by nurses
Real-time tracking to patient-reporting symptoms
Automated alerts for early identification of signs and symptoms to anticipate SAEs apparition
Centralized access to patient data across visits
Easier coordination with investigators for timely intervention
Reduces manual workload while increasing data reliability
Weekly reporting of symptoms based on trial-specific PRO-CTCAE (NCI Standard) questionnaire
Actionable tips and feedback from the HCP based on the answers to the questionnaire
Comprehensive PRO library including Quality of Life (QLQ-C30, EQ-5D-5L, etc.), Social Determinants of Health, and many others.
Integration with external devices: Step count, SPO2, etc.
Library of content (videos, articles, podcasts) driving patient engagement, validated by IRBs
Acces through BYOD (Bring Your Own Device) or Provisioned Device
Centralized oversight across all sites and patient cohorts: intuitive dashboards for trial activity and site performance
Real-time inclusion and recruitment tracking via Resilience
Automated monitoring of patient adherence and engagement
Anticipation for protocol deviations and operational risks
Simplified reporting to reduce manual workload
Compare trial arms in real time to support dose selection
Optimize dose escalation with FDA-aligned PRO-CTCAE insights
Benchmark against Resilience’s Real-World Data for Standard of Care context
Generate clinical evidence that strengthens Phase 3 go/no-go decisions
Build robust submissions with regulatory-grade patient data